Vorapaxar

1. Vorapaxar decreases cellular senescence in Mammalia.

   “THBD signaling depletion or inhibition using vorapaxar, an FDA-approved drug, effectively ablates senescent cells and restores tissue homeostasis in liver fibrosis models”

   Animalsin liver fibrosis models

   Antagonizing the irreversible thrombomodulin-initiated proteolytic signaling alleviates age-related liver fibrosis via senescent cell killing

   Cell research·May 11, 2023

2. Vorapaxar decreases cellular senescence in mice.

   “Inhibiting PAR1 signaling with vorapaxar interrupts this process, reduces the burden of 'undead' senescent cells, and safely improves NASH and fibrosis despite ongoing lipotoxic stress.”

   Animalsin mouse models of NASH

   Targeting senescent hepatocytes using the thrombomodulin-PAR1 inhibitor vorapaxar ameliorates NAFLD progression

   Hepatology (Baltimore, Md.)·Apr 11, 2023

More on Cellular senescence

1. Vorapaxar decreases liver fibrosis in Mammalia.

   “THBD signaling depletion or inhibition using vorapaxar, an FDA-approved drug, effectively ablates senescent cells and restores tissue homeostasis in liver fibrosis models”

   Animalsin liver fibrosis models

   Antagonizing the irreversible thrombomodulin-initiated proteolytic signaling alleviates age-related liver fibrosis via senescent cell killing

   Cell research·May 11, 2023

More on Liver fibrosis

1. Vorapaxar decreases liver fibrosis in mice.

   “safely improves NASH and fibrosis despite ongoing lipotoxic stress”

   Animalsin mouse models of NASH

   Targeting senescent hepatocytes using the thrombomodulin-PAR1 inhibitor vorapaxar ameliorates NAFLD progression

   Hepatology (Baltimore, Md.)·Apr 11, 2023